Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD
A double-blinded randomized clinical trial
Keywords:
Methylphenidate; Attention Deficit/Hyperactivity Disorder; Unsaturated Fatty AcidsAbstract
Background: In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.
Objective: The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients with ADHD in Zahedan, Iran.
Methods: In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.
Results: Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven children (17.5%) were girls. Mean severity of signs in the group under methylphenidate plus PUFA treatment was 39.9±4.9 before treatment and 20.1±6.0 after 8 weeks of treatment (p<0.001). Mean severity of signs in the group under methylphenidate plus placebo treatment was 41.2±2.7 before treatment and 26.1±9.0 after 8 weeks of treatment (p<0.001). Mean reduction in the severity of symptoms in the group under methylphenidate therapy was 19.7±5.9 and in PUFA and placebo group it was 15.1±9.3 (p<0.067). Response to treatment (a reduction of at least 25% in the signs) in the group taking methylphenidate plus PUFA was 90% (18 patients) and in methylphenidate plus placebo group, it was 60% (12 patients) (p=0.028).
Conclusion: This study shows that PUFA is an efficient nutrient to treat ADHD and it can be used to treat patients. However, definitive conclusion requires repeating the study with a larger sample and longer study period.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015092724209N2.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Qiu J, Hong Q, Chen RH, Tong ML, Zhang M, Fei L, et al. Gene expression profiles in the prefrontal
cortex of SHR rats by cDNA microarrays. Mol Biol Rep. 2010; 37(4): 1733-40. doi: 10.1007/s11033-009- 9596-1. PMID: 19572212.
Wei JL, Bond J, Mayo MS, Smith HJ, Reese M, Weatherly RA. Improved behavior and sleep after
adenotonsillectomy in children with sleep-disordered breathing: long-term follow-up. Arch Otolaryngol
Head Neck Surg. 2009; 135(7): 642-6. doi: 10.1001/archoto.2009.74. PMID: 19620583.
Joo EJ, Greenwood TA, Schork N, McKinney RA, Sadovnick AD, Remick RA, et al. Suggestive evidence
for linkage of ADHD features in bipolar disorder to chromosome 10p14. Am J Med Genet B
Neuropsychiatr Genet. 2010; 153B(1): 260-8. doi: 10.1002/ajmg.b.31005. PMID: 19603423.
American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with
attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics. 2000; 105(5): 1158- 70. doi: 10.1542/peds.105.5.1158. PMID: 10836893.
Greenhill LL, Hechtman LI. Attention-Deficit/Hyperactivity Disorder. In: Sadock BJ, Sadock VA, Ruiz
P.(eds). Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia (PA): Lippincott, Williams &
Wilkins. 2009; 3560-72.
Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of psychiatry, behavioral clinical psychiatry.10 th
ed. Philadelphia (PA): Lippincott, Williams & Wilkins. 2007; 1206-17.
Anderson GM, Martin A. Neurochemistry pharmacodynamic and biological psychiatry. Spetie L, Arnold
LE. Attention-Deficit/Hyperactivity Disorder. In: Martin A, VolkmarFR. (eds). Lewis's Child and
Adolescent Psychiatry: A Comprehensive Textbook, 4th ed. Philadelphia (PA): Lippincott, Williams &
Wilkins. 2007; 240- 3, 430-49.
Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state
and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003; 42(1): 33-84. doi:
1016/S0165-0173(03)00143-7. PMID: 12668290.
Baker GB, Bornstein RA, Douglass AB, Van Muyden JC, Ashton S, Bazylewich TL. Urinary excretion of
MHPG and normetanephrine in attention deficit hyperactivity disorder. Mol Chem Neuropathol. 1993;
(1-2): 173-8. doi: 10.1007/BF03160031. PMID: 8466590.
Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have
wecome in 50 years? J Am Acad Child Adolesc Psychiatry. 1987; 26(5): 676-86. doi: 10.1097/00004583- 198709000-00011. PMID: 2889717.
Mefford IN, Potter WZ. A neuroanatomical and biochemical basis for attention deficit disorder with
hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation.
Med Hypotheses. 1989; 29(1): 33-42. doi: 10.1016/0306-9877(89)90164-3. PMID: 2546021.
Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current
perspectives. J Am Acad Child Adolesc Psychiatry. 1996; 35(3): 264-72. doi: 10.1097/00004583- 199603000-00006. PMID: 8714313.
Anderson GM, Dover MA, Yang BP, Holahan JM, Shaywitz SE, Marchione KE, et al. Adrenomedullary
function during cognitive testing in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc
Psychiatry. 2000; 39(5): 635-43. doi: 10.1097/00004583-200005000-00018. PMID: 10802982.
Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child,
adolescent, and adult. Dis Mon. 2007; 53(2): 70-131. doi: 10.1016/j.disamonth.2007.01.001. PMID:
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD: clinical practice
guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children
and adolescents. Pediatrics. 2011; 128(5): 1007-22. doi: 10.1542/peds.2011-2654. PMID: 22003063,
PMCID: PMC4500647.
Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity
disorder. J Clin Psychopharmacol. 2008; 28(3 Suppl 2): S46-53. doi: 10.1097/JCP.0b013e318173312f.
PMID: 18480677.
Watson SM, Richels C, Michalek AP, Raymer A. Psychosocial treatments for ADHD: a systematic
appraisal of the evidence. J Atten Disord. 2015; 19(1): 3-10. doi: 10.1177/1087054712447857. PMID:
Verma R, Balhara YP, Mathur S. Management of attention-deficit hyperactivity disorder. J Pediatr
Neurosci. 2011; 6(1): 13-8. doi: 10.4103/1817-1745.84400. PMID: 21977081, PMCID: PMC3173906.
Weiss M, Weiss G. Attention Deficit Hyperactivity Disorder. In: Lewis M (ed). Child and adolescent
Psychiatry. 3rd ed. Philadelphia: Lippincott Williams &Wilkins. 2002: 645-65.
Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, et al. A high ratio of dietary n-6/n- 3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res. 2011; 31(1): 1- 8. doi: 10.1016/j.nutres.2011.01.002. PMID: 21310299.
Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, et al. Dietary intake of
n-3 and n-6 fatty acids and the risk of prostate cancer. Am J ClinNutr. 2004; 80(1): 204-16. PMID:
Astorg P. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of
epidemiological and experimental evidence. Cancer Causes Control. 2004; 15(4): 367-86. doi:
1023/B:CACO.0000027498.94238.a3. PMID: 15141138.
Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with
attention-deficit hyperactivity disorder. Am J Clin Nutr. 2000; 71(1Suppl): 327S-30S. PMID: 10617991.
Stevens LJ, Zentall SS, Abate ML, Kuczek T, Burgess JR. Omega-3 fatty acids in boys with behavior,
learning, and health problems. Physiol Behav. 1996; 59(4-6): 915-20. doi: 10.1016/0031-9384(95)02207-4.
PMID: 8778886.
Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder.
Prostaglandins Leukot Essent Fatty Acids. 2000; 63(1-2): 79-87. doi: 10.1054/plef.2000.0196. PMID:
Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al. Essential fatty acid metabolism in
boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995; 62(4): 761-8. PMID: 7572706.
Brenna JT, Diau GY. The influence of dietary docosahexaenoic acid and arachidonic acid on central
nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids. 2007;
(5-6): 247-50. doi: 10.1016/j.plefa.2007.10.016. PMID: 18023566, PMCID: PMC2174532.
McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: Potential
implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty
Acids. 2006; 75(4-5): 329-49. doi: 10.1016/j.plefa.2006.07.010. PMID: 16949263.
Champeil-Potokar G, Chaumontet C, Guesnet P, Lavialle M, Denis I. Docosahexaenoic acid (22:6n-3)
enrichment of membrane phospholipids increases gap junction coupling capacity in cultured astrocytes. Eur
J Neurosci. 2006; 24(11): 3084-90. doi: 10.1111/j.1460-9568.2006.05185.x. PMID: 17156369.
Song C, Li X, Kang Z, Kadotomi Y. Omega-3 fatty acid ethyleicosapentaenoate attenuates IL-1betainduced changes in dopamine and metabolites in the shell of the nucleus accumbens: Involved with PLA2
activity and corticosterone secretion. Neuropsychopharmacology. 2007; 32(3): 736-44. doi:
1038/sj.npp.1301117. PMID: 16794572.
Song C, Horrobin D. Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory
impairment induced by central IL-1beta administration. J Lipid Res. 2004; 45(6): 1112-21. doi:
1194/jlr.M300526-JLR200. PMID: 15060086.
Frasure-Smith N, Lesperance F, Julien P. Major depression is associated with lower omega-3 fatty acid
levels in patients with recent acute coronary syndromes. Biol Psychiatry. 2004; 55(9): 891-6. doi:
1016/j.biopsych.2004.01.021. PMID: 15110732.
Bélanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippé S, L'heureux F, et al. Omega-3 fatty acid
treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo- controlled study. Paediatr Child Health. 2009; 14(2): 89-98. PMID: 19436468, PMCID: PMC2661342.
Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled trail of dietary
supplementation with fatty acids in children with developmental coordination-disorder. Pediatrics. 2005;
(5): 1360-6. doi: 10.1542/peds.2004-2164. PMID: 15867048.
Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmetal disorders. Int Rev
Psychiatry. 2006; 18(2): 155-72. doi: 10.1080/09540260600583031. PMID: 16777670.
Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and autistic spectrum.
Prostaglandins Leukot Essent Fatty Acids. 2004; 70(4): 383-90. doi: 10.1016/j.plefa.2003.12.020. PMID:
Gustafsson PA, Birberg-Thornberg U, Duchén K, Landgren M, Malmberg K, Pelling H, et al. EPA
supplementation improves teacher rated behaviour and oppositional symptoms in children with ADHD.
Acta Paediatr. 2010; 99(10): 1540-9. doi: 10.1111/j.1651-2227.2010.01871.x. PMID: 20491709.
Gillies D, Sinn JKh, Lad SS, Leach MJ, Ross MJ. Polyunsaturated fatty acids (PUFA) for attention deficit
hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2012; 7:
CD007986. doi: 10.1002/14651858.cd007986.pub2. PMID: 22786509.
Laasonen M, Hokkanen L, Leppämäki S, Tani P, Erkkilä AT. Project DyAdd: Fatty acids in adult dyslexia,
ADHD, and their comorbid combination. Prostaglandins Leukot Essent Fatty Acids. 2009; 81(1): 89-96.
doi: 10.1016/j.plefa.2009.04.005. PMID: 19523794.
Ng KH, Meyer BJ, Reece L, Sinn N. Dietary PUFA intakes in children with attention-deficit/hyperactivity
disorder symptoms. Br J Nutr. 2009; 102(11): 1635-41. doi: 10.1017/S0007114509990821. PMID:
Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev
Med Child Neurol. 2009; 51(8): 580-92. doi: 10.1111/j.1469-8749.2009.03351.x. PMID: 19549202.
Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid–containing food administration in
symptoms of attention–deficit hyperactivity disorder-a placebo-controlled double-blind study. Eur J Clin
Nutr. 2004; 58(3): 467-73. doi: 10.1038/sj.ejcn.1601830. PMID: 14985685.
Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning
and behavior problems associated with child ADHD. J Dev Behav Pediatr. 2007; 28(2): 82-91. doi:
1097/01.dbp.0000267558.88457.a5.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
